company:weight-watchers Novo's expanding collaboration with Weight Watchers Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
drug:wegovy Less for Less: CVS drops Zepbound for Wegovy CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
chemical:semaglutide After two months, Novo Nordisk and HIMS part ways Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
company:novo-nordisk Novo Nordisk patent protections lapse in Canada Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
drug:wegovy Wegovy in pill form is coming Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
company:novo-nordisk Novo Nordisk offers cheaper Wegovy Novo Nordisk makes available cheaper Wegovy, via it's savings plan, purchasable at local pharmacies.
category:watercooler Shortages threaten corporate profits, likely to end soon We think the GLP1 shortage is going to end in the first half of 2025. Here's why.
category:news Ozempic approved for Chronic Kidney Disease The FDA has approved Semaglutide for chronic kidney disease. We explore research and the possible implications for insurance coverage and more.
government Government Price negotiations on Ozempic and Wegovy The government has selected Ozempic and Wegovy for price negotiations -- are we going to see cheaper prices?
category:benefits Zepbound coverage for Sleep Apnea gets Agency approval Center for Medicare and Medicaid declared that Zepbound is covered by insurance for treating Sleep Apnea, given it's effectiveness.
categeory:watercooler What people get wrong about Ozempic We debunk some common misconceptions about GLP1 drugs like Ozempic, Wegovy, Mounjaro and others.
drug:wegovy Featured FDA approves Wegovy for reducing heart disease risk FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or OverweightThe FDA approved a new use for a drug to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.FDAOffice of the Commissioner In great
